Akero Therapeutics Inc (AKRO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Andrew Cheng
Employees:
30
170 HARBOR WAY, SOUTH SAN FRANCISCO, CA 94080
650-487-6488

Akero Therapeutics, Inc. engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metaboli® of lipids, carbohydrates, and proteins.

Data derived from most recent annual or quarterly report
Market Cap 1.526 Billion Shares Outstanding35.01 Million Avg 30-day Volume 597.567 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.7
Price to Revenue0.0 Debt to Equity0.0275 EBITDA-121.478 Million
Price to Book Value3.8325 Operating Margin0.0 Enterprise Value951.935 Million
Current Ratio14.972 EPS Growth-0.175 Quick Ratio14.816
1 Yr BETA -0.041 52-week High/Low 48.24 / 7.52 Profit Margin0.0
Operating Cash Flow Growth-22.6797 Altman Z-Score20.5822 Free Cash Flow to Firm -80.928 Million
Earnings Report2023-02-24
View SEC Filings from AKRO instead.

View recent insider trading info

Funds Holding AKRO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AKRO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-13:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-25:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-11-12:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    2.1 Million total shares from 37 transactions

    Exercise Derivative Conversion (M)

    62.5 Thousand total shares from 6 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CHENG ANDREW PRESIDENT & CEO

    • Officer
    • Director
    521,016 2022-12-01 10

    SKORPIOS TRUST

    BLUE HORIZON ENTERPRISE LTD

    EZBON INTERNATIONAL LTD

    MONTRAGO TRUSTEES LTD

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    3,271,829 2022-12-01 1

    HARRISON SETH LORING

    • Director
    284,364 2022-11-30 4

    ROLPH TIMOTHY CHIEF SCIENTIFIC OFFICER

    • Officer
    183,837 2022-11-15 7

    YALE CATRIONA CHIEF DEVELOPMENT OFFICER

    • Officer
    72,073 2022-11-10 4

    YOUNG JONATHAN CHIEF OPERATING OFFICER

    • Officer
    283,510 2022-10-25 3

    WHITE WILLIAM RICHARD CHIEF FINANCIAL OFFICER

    • Officer
    266,258 2022-10-13 6

    IWICKI MARK T

    • Director
    15,000 2022-06-02 1

    HENDERSON JANE

    • Director
    15,000 2022-06-02 1

    GRAHAM G. WALMSLEY

    • Director
    15,000 2022-06-02 1

    HEYMAN TOMAS J.

    • Director
    15,000 2022-06-02 1

    XU YUAN

    • Director
    15,000 2022-06-02 1

    JUDY CHOU

    • Director
    15,000 2022-06-02 1

    ATP LIFE SCIENCE VENTURES, L.P.

    ATP III GP, LTD.

    • 10% Owner
    No longer subject to file 2021-06-28 0

    BITTERMAN KEVIN

    • Director
    2,232,251 2021-06-01 0

    VENBIO GLOBAL STRATEGIC FUND II L.P.

    VENBIO GLOBAL STRATEGIC GP II, L.P.

    VENBIO GLOBAL STRATEGIC GP II, LTD.

    ADELMAN ROBERT J

    GOODMAN COREY S

    • 10% Owner
    3,033,552 2020-07-01 0

    ATLAS VENTURE OPPORTUNITY FUND I, L.P.

    • 10% Owner
    404,079 2020-02-07 0

    VERSANT VENTURE CAPITAL VI, L.P.

    VERSANT VENTURES VI GP, L.P.

    VERSANT VENTURES VI GP-GP, LLC

    • 10% Owner
    3,092,698 2020-01-16 0

    ATLAS VENTURE FUND XI, L.P.

    • 10% Owner
    2,706,412 2019-12-31 0

    VERSANT VENTURE CAPITAL VI, L.P.

    • 10% Owner
    3,656,585 2019-12-27 0

    ATLAS VENTURE FUND XI, L.P.

    ATLAS VENTURE OPPORTUNITY FUND I, L.P.

    • 10% Owner
    3,403,884 2019-12-17 0

    REDMILE GROUP, LLC

    GREEN JEREMY

    • 10% Owner
    No longer subject to file 2019-06-24 0

    ATLAS VENTURE FUND XI, L.P.

    ATLAS VENTURE ASSOCIATES XI, LLC

    ATLAS VENTURE ASSOCIATES XI, L.P.

    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.

    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC

    ATLAS VENTURE OPPORTUNITY FUND I, L.P.

    • 10% Owner
    3,974,858 2019-06-24 0

    ROYSTON AARON

    • Director
    3,954,858 2019-06-24 0

    APPLE TREE PARTNERS IV, L.P.

    ATP III GP, LTD.

    HARRISON SETH LORING

    • Director
    • 10% Owner
    0 2019-06-19 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SKORPIOS TRUST FORMER 10% OWNER see footnote

    BLUE HORIZON ENTERPRISE LTD FORMER 10% OWNER see footnote

    EZBON INTERNATIONAL LTD FORMER 10% OWNER see footnote

    MONTRAGO TRUSTEES LTD FORMER 10% OWNER see footnote

    2022-12-05 16:36:52 -0500 2022-12-01 S 1,636,000 $43.50 d 3,271,829 indirect 1.4925 1.4925 2 0.0 1

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    2022-12-02 17:52:29 -0500 2022-12-01 M 10,000 d 210,868 direct yes

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    2022-12-02 17:52:29 -0500 2022-12-01 S 10,000 $46.07 d 310,148 direct yes -5.6338 0.0 1 -5.6338 2

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    2022-12-02 17:52:29 -0500 2022-12-01 M 10,000 $0.62 a 320,148 direct yes -5.6338 0.0 1 -5.6338 2

    HARRISON SETH LORING - Director see footnote

    2022-12-02 17:48:56 -0500 2022-11-30 S 6,851 $46.44 d 153,242 indirect -5.6338 0.0 1 -5.6338 2

    HARRISON SETH LORING - Director

    2022-12-02 17:48:56 -0500 2022-11-30 S 6,322 $46.44 d 141,080 direct -5.6338 0.0 1 -5.6338 2

    HARRISON SETH LORING - Director see footnote

    2022-12-02 17:48:56 -0500 2022-11-30 S 5,179 $47.60 d 148,063 indirect -5.6338 0.0 1 -5.6338 2

    HARRISON SETH LORING - Director

    2022-12-02 17:48:56 -0500 2022-11-30 S 4,779 $47.60 d 136,301 direct -5.6338 0.0 1 -5.6338 2

    ROLPH TIMOTHY - Officer CHIEF SCIENTIFIC OFFICER

    2022-11-16 19:15:33 -0500 2022-11-16 S 100 $46.05 d 183,837 direct yes -0.6521 3.0807 3.0807 6 -1.3492 4

    ROLPH TIMOTHY - Officer CHIEF SCIENTIFIC OFFICER

    2022-11-16 19:15:33 -0500 2022-11-16 S 3,847 $45.45 d 183,937 direct yes -0.6521 3.0807 3.0807 6 -1.3492 4

    ROLPH TIMOTHY - Officer CHIEF SCIENTIFIC OFFICER

    2022-11-16 19:15:33 -0500 2022-11-15 S 3,138 $45.04 d 187,784 direct yes -0.6521 3.0807 3.0807 6 -1.3492 4

    YALE CATRIONA - Officer CHIEF DEVELOPMENT OFFICER

    2022-11-14 17:26:43 -0500 2022-11-10 S 4,900 $39.41 d 72,173 direct yes 2.1438 -2.0322 2.1438 2 -2.0322 6

    YALE CATRIONA - Officer CHIEF DEVELOPMENT OFFICER

    2022-11-14 17:26:43 -0500 2022-11-10 S 100 $39.96 d 72,073 direct yes 2.1438 -2.0322 2.1438 2 -2.0322 6

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    2022-11-02 21:52:32 -0400 2022-11-01 M 10,000 d 220,868 direct yes

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    2022-11-02 21:52:32 -0400 2022-11-01 M 10,000 $0.62 a 320,148 direct yes -6.0547 -3.5889 0.0 1 -6.8115 3

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    2022-11-02 21:52:32 -0400 2022-11-01 S 8,900 $43.47 d 310,648 direct yes -6.0547 -3.5889 0.0 1 -6.8115 3

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    2022-11-02 21:52:32 -0400 2022-11-01 S 600 $42.15 d 319,548 direct yes -6.0547 -3.5889 0.0 1 -6.8115 3

    CHENG ANDREW - Director - Officer PRESIDENT & CEO

    2022-11-02 21:52:32 -0400 2022-11-01 S 500 $44.02 d 310,148 direct yes -6.0547 -3.5889 0.0 1 -6.8115 3

    HARRISON SETH LORING - Director see footnote

    2022-11-01 17:38:03 -0400 2022-10-28 S 869 $41.12 d 160,093 indirect -2.2668 -8.1365 0.0 1 -8.9239 4

    HARRISON SETH LORING - Director

    2022-11-01 17:38:03 -0400 2022-10-28 S 800 $41.12 d 147,402 direct -2.2668 -8.1365 0.0 1 -8.9239 4

    HARRISON SETH LORING - Director

    2022-11-01 17:38:03 -0400 2022-10-28 S 20,338 $40.28 d 148,202 direct -2.2668 -8.1365 0.0 1 -8.9239 4

    HARRISON SETH LORING - Director see footnote

    2022-11-01 17:38:03 -0400 2022-10-28 S 22,096 $40.28 d 160,962 indirect -2.2668 -8.1365 0.0 1 -8.9239 4

    HARRISON SETH LORING - Director see footnote

    2022-10-27 21:50:11 -0400 2022-10-27 S 23,719 $42.03 d 187,071 indirect 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director

    2022-10-27 21:50:11 -0400 2022-10-27 S 21,830 $42.03 d 172,233 direct 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director see footnote

    2022-10-27 21:50:11 -0400 2022-10-27 S 4,013 $43.23 d 183,058 indirect 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director

    2022-10-27 21:50:11 -0400 2022-10-27 S 40,903 $41.12 d 194,063 direct 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director see footnote

    2022-10-27 21:50:11 -0400 2022-10-27 S 44,440 $41.12 d 210,790 indirect 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director

    2022-10-27 21:50:11 -0400 2022-10-27 S 3,693 $43.23 d 168,540 direct 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director see footnote

    2022-10-27 21:50:11 -0400 2022-10-26 S 38,961 $43.08 d 287,852 indirect 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director

    2022-10-27 21:50:11 -0400 2022-10-26 S 35,860 $43.08 d 264,991 direct 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director see footnote

    2022-10-27 21:50:11 -0400 2022-10-26 S 20,085 $44.90 d 255,230 indirect 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director

    2022-10-27 21:50:11 -0400 2022-10-26 S 18,486 $44.90 d 234,966 direct 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director see footnote

    2022-10-27 21:50:11 -0400 2022-10-26 S 12,537 $43.97 d 275,315 indirect 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director

    2022-10-27 21:50:11 -0400 2022-10-26 S 11,539 $43.97 d 253,452 direct 3.5531 -5.7094 6.2485 3 -5.7094 6

    ROLPH TIMOTHY - Officer CHIEF SCIENTIFIC OFFICER

    2022-10-27 21:27:11 -0400 2022-10-26 S 4,762 $45.03 d 190,922 direct yes 3.5531 -5.7094 6.2485 3 -5.7094 6

    ROLPH TIMOTHY - Officer CHIEF SCIENTIFIC OFFICER

    2022-10-27 21:27:11 -0400 2022-10-25 M 8,203 $6.36 a 204,540 direct yes 3.5531 -5.7094 6.2485 3 -5.7094 6

    YOUNG JONATHAN - Officer CHIEF OPERATING OFFICER

    2022-10-27 21:25:35 -0400 2022-10-25 M 12,500 $6.36 a 175,754 direct yes 3.5531 -5.7094 6.2485 3 -5.7094 6

    YOUNG JONATHAN - Officer CHIEF OPERATING OFFICER

    2022-10-27 21:25:35 -0400 2022-10-25 S 12,500 $44.72 d 163,254 direct yes 3.5531 -5.7094 6.2485 3 -5.7094 6

    YOUNG JONATHAN - Officer CHIEF OPERATING OFFICER

    2022-10-27 21:25:35 -0400 2022-10-25 M 12,500 d 60,256 direct yes

    ROLPH TIMOTHY - Officer CHIEF SCIENTIFIC OFFICER

    2022-10-27 21:27:11 -0400 2022-10-25 M 1,797 $28.35 a 206,337 direct yes 3.5531 -5.7094 6.2485 3 -5.7094 6

    ROLPH TIMOTHY - Officer CHIEF SCIENTIFIC OFFICER

    2022-10-27 21:27:11 -0400 2022-10-25 M 1,797 d 75,783 direct yes

    ROLPH TIMOTHY - Officer CHIEF SCIENTIFIC OFFICER

    2022-10-27 21:27:11 -0400 2022-10-25 M 8,203 d 48,225 direct yes

    ROLPH TIMOTHY - Officer CHIEF SCIENTIFIC OFFICER

    2022-10-27 21:27:11 -0400 2022-10-25 S 10,653 $45.09 d 195,684 direct yes 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director

    2022-10-27 21:50:11 -0400 2022-10-25 S 4,515 $44.92 d 300,851 direct 3.5531 -5.7094 6.2485 3 -5.7094 6

    HARRISON SETH LORING - Director see footnote

    2022-10-27 21:50:11 -0400 2022-10-25 S 4,906 $44.92 d 326,813 indirect 3.5531 -5.7094 6.2485 3 -5.7094 6

    WHITE WILLIAM RICHARD - Officer CHIEF FINANCIAL OFFICER

    2022-10-17 17:40:29 -0400 2022-10-13 M 20,000 d 261,829 direct yes

    WHITE WILLIAM RICHARD - Officer CHIEF FINANCIAL OFFICER

    2022-10-17 17:40:29 -0400 2022-10-13 S 20,000 $39.82 d 4,429 direct yes -0.8055 7.2248 13.4977 13.4977 31 -6.8343 15

    WHITE WILLIAM RICHARD - Officer CHIEF FINANCIAL OFFICER

    2022-10-17 17:40:29 -0400 2022-10-13 M 20,000 $7.01 a 24,429 direct yes -0.8055 7.2248 13.4977 13.4977 31 -6.8343 15

    YALE CATRIONA - Officer CHIEF DEVELOPMENT OFFICER

    2022-10-12 16:59:55 -0400 2022-10-10 S 5,000 $37.99 d 77,073 direct yes -4.1812 0.1493 14.0866 14.0866 31 -5.0025 18

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AKERO THERAPEUTICS INC AKRO 2022-12-09 18:15:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 17:45:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 17:15:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 16:45:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 16:15:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 15:45:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 15:15:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 14:45:04 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 14:15:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 13:45:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 13:15:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-09 12:45:03 UTC 3.4119 0.4081 400000
    AKERO THERAPEUTICS INC AKRO 2022-12-08 22:15:03 UTC 3.4119 0.4081 450000
    AKERO THERAPEUTICS INC AKRO 2022-12-08 21:45:04 UTC 3.4028 0.4172 450000
    AKERO THERAPEUTICS INC AKRO 2022-12-08 21:15:03 UTC 3.4028 0.4172 450000
    AKERO THERAPEUTICS INC AKRO 2022-12-08 20:45:04 UTC 3.3897 0.4303 450000
    AKERO THERAPEUTICS INC AKRO 2022-12-08 20:15:05 UTC 3.3897 0.4303 450000
    AKERO THERAPEUTICS INC AKRO 2022-12-08 19:45:04 UTC 3.3897 0.4303 450000
    AKERO THERAPEUTICS INC AKRO 2022-12-08 19:15:03 UTC 3.3897 0.4303 450000
    AKERO THERAPEUTICS INC AKRO 2022-12-08 18:45:04 UTC 3.1695 0.6505 450000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Index Plus All-Cap Fund AKRO -3.0 shares, $-63.6 2020-03-31 N-PORT
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund AKRO -4150.0 shares, $-42496.0 2022-07-31 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund AKRO -1212.0 shares, $-12410.88 2022-07-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments